Skip to main content

Influenza, Human

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
NCT01863433 | PHASE 4 | INTERVENTIONAL

This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged between 18 and 60 years.

Trial Information
1 Sites
120 Participants
Recruiting
18 Years to 59 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
London,United Kingdom,NW107EW

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov